Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01272141 · ClinicalTrials.gov registry record · Phase 2
A Study of Lapatinib in Combination With Everolimus in Patients With Advanced, Triple Negative Breast Cancer
A Phase 2 study, sponsored by Emory University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT01272141: Clinical Trial Phase 2 study, sponsored by Emory University.
NCT01272141 is a Phase 2 study that was terminated before completion, run by Emory University. The registered enrollment target is 5 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01272141, a Phase 2 study, was terminated before completion, sponsored by Emory University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
The patient is being asked to join this clinical research study to find out if lapatinib, an agent that targets a protein, called epidermal growth factor receptor (EGFR) on the surface of cancer cells in combination with everolimus, an agent that targets a protein in the cancer cell, called mammalian target of rapamycin (mTOR) is effective in metastatic triple negative breast cancers that are no longer controlled by standard chemotherapy.
Interventions
- DRUG Lapatinib and Everolimus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2010-12 |
| Est. Completion | 2014-01 |
| Phase | Phase 2 |
Why NCT01272141 stopped before completion
NCT01272141 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 1 intervention - of which Lapatinib and Everolimus is the first listed.
NCT01272141 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01272141 about?
NCT01272141 is a clinical study titled "A Study of Lapatinib in Combination With Everolimus in Patients With Advanced, Triple Negative Breast Cancer". The patient is being asked to join this clinical research study to find out if lapatinib, an agent that targets a protein, called epidermal growth factor receptor (EGFR) on the surface of cancer cells in combination with everolimus, an agent that targets a protein in the cancer cell, called mammalia...
What is the current status of trial NCT01272141?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2010-12. Estimated completion is 2014-01.
What interventions are being tested in trial NCT01272141?
The interventions under investigation include: Lapatinib and Everolimus (DRUG).
Who is sponsoring clinical trial NCT01272141?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01272141's enrollment target sits among peer trials
5 2000th of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia